Discover how we work
We open doors
to connect
the dots.

Who are we?

The LEO Science & Tech Hub is a R&D innovation unit of LEO Pharma. We explore cutting-edge science and technology opportunities with relevance to dermatology. By partnering with public and private institutions in the world’s leading life science cluster in Boston, we act as a catalyst to transform early-stage innovations and technologies into solutions that will improve the quality of life for people with skin diseases. LEO Science & Tech Hub was officially inaugurated in September 2016.
Engage with us
What can help us to create valid and how re with partners that can help us to create valid and how reliable alternatives to skin biopsies in order we want tResearch Areas
What can help us to create valid and how re with partners that can help us to create valid and how reliable alternatives to skin biopsies in order we want tEngage with us
What can help us to create valid and how re with partners that can help us to create valid and how reliable alternatives to skin biopsies in order we want tVisit www.leo-pharma.com

Precision Medicine in Dermatology.

Precision medicine aims at identifying the most suitable treatment for each individual patient.

In order to achieve this we will require a much deeper understanding about the different factors that contribute to the course of disease between patients with the same disease such as:

Environmental. Genetic. Molecular. Environmental. Genetic. Molecular.

Our current research projects aim at developing technologies that should enable us to adress these questions, resulting in solutions that can one day support treatment decisions.

News from the hub

Dec. 2018 12 AID, HMI, and LEO Science & Tech Hub announce winners of Hacking Dermatology

Advancing Innovation in Dermatology (AID), Hacking Medicine Institute (HMi), and LEO Science & Tech Hub, the Boston-based R&D innovation unit of LEO Pharma, officially announce the final winners of Hacking Dermatology. Awardees include Lucid, a personalized and automated home patch testing solution, RxThat, an online prescription marketplace and management application, and MatchLab, a skin-image analysis service that provides image tracking and datasets for use in AI diagnostic models.

Hacking Dermatology, in a 12-month process,  brought together clinical and scientific experts, patients, engineers, and innovators to reimagine the landscape of patient access to dermatological intervention. At the start of the initiative in April of this year, over 40 experts came together to identify the biggest challenges in this field. Next, over 120 participants and mentors formed 20 teams at a hackathon in June, where they spent three packed days learning about the challenges and developing solutions to address them. At the end of the hackathon, 5 teams were awarded $5,000 each to enter a condensed incubation period. During this time they honed their ideas, did market research, and fleshed out pitches.

In October, these teams came before a panel of expert judges to compete for $55,000 in grants. This final pitch competition in October was hosted by HMi and its affiliated organization MIT Hacking Medicine and was held at MIT’s Sloan School of Management.  The top three teams were awarded these grants were entered into an acceleration period where they will receive mentorship and access to resources in order to advance their solutions to market.

The 1st place team, Lucid, is focused on at home patch testing for targeted allergies. One of the team’s co-founders, Sameer Gupta, spoke about the support his team received throughout the process, “Through the hackathon experience, we were able to reflect on inefficiencies in current allergy diagnostics, to imagine a more personalized and accessible solution, and to develop a viable product with maximal benefit for patients.”

Nick Rance, a co-founder of another one of the winning teams, reflected on the process, “Hacking Dermatology was instrumental in helping us conceptualize and develop MatchLab AI. They prioritized our mission and were extremely proactive in providing advice and sharing their knowledge. The partnership also helped us form important relationships with dozens of industry experts who have been critical to our development, which otherwise would not have been possible.”

Hacking Dermatology focused on challenges related to artificial intelligence in dermatology, diagnosis, measurement and evaluation of chronic skin disease, treatment costs, and topical delivery of medications. Over 40 mentors joined the project and each brought a critical, expert perspective on the identified challenges. James Allred, M.D., is the Chief Clinical Adviser of RxThat, another one of the three finalist teams. He described the nurturing environment that the initiative provided to boost team productivity: “Their mentorship helped refine our technology and service offerings for key stakeholders within the healthcare delivery ecosystem and further inspired our commitment to improving the patient journey for those living with skin disease.”

Hacking Dermatology was modeled on the Hacking Medicine Institute’s extended innovation program, and was the result of a productive partnership between AID, HMi, and LEO Science & Tech Hub. “The level of talent we witnessed among the participants validated our vision and goal of creating a blueprint for a hackathon tailored to our field of work,” said Alex Costa, Senior Technology and Innovation Manager of LEO Science & Tech Hub. “This event exceeded our expectations. Some truly great ideas were developed and choosing winners was not an easy process. We wish all of them luck as they continue their work.”

“Initiatives like Hacking Dermatology are of ever-growing importance to our field,” said Adam Raff, MD, PhD, Education Committee Member at Advancing Innovation in Dermatology and Physician at Massachusetts General Hospital. “True innovation requires collective effort and it was inspiring to see such a diverse group of students and professionals come together to solve some of the industry’s most pressing issues.”

“LEO Science & Tech Hub and AID are both organizations that value open science and innovation and as a result, their businesses are structured around processes, support services and an overall mindset that helps maximize the potential of new ideas,” said Laura Duerksen, Executive Director of Hacking Medicine Institute. “In implementing the HMi pipeline of innovation, which involves a wide base of health system stakeholders and experts, we were able to successfully seed new ideas from the theme of the dermatological patient journey. We look forward to expanding on our relationship with AID and LEO in the future.”

About Hacking Medicine Institute + MIT Hacking Medicine

HMi is an educational 501c3 that practices and studies contemporary healthcare innovation, by working with industry and academic partners to organize hackathons and challenges and by studying the process of innovation and publishing on findings. These complimentary, parallel programs allow for the active progress of healthcare innovation through critical and evidenced based strategies.

MIT Hacking Medicine is a group founded at MIT in 2011, comprising of MIT students and community members, aimed at energizing the healthcare community and accelerating medical innovation. We accomplish this by carrying out health hackathons, design thinking workshops, and networking gatherings to teach healthcare entrepreneurship and develop digital strategies to scale medicine as a way to solve health problems worldwide. To date, the group has organized more than 150 events across 15 countries and 5 continents with over 40 companies, raising over $200M in venture funding.

About Advancing Innovation in Dermatology (AID)

Advancing Innovation in Dermatology (AID) is a non-profit organization committed to catalyzing the development of new solutions that can significantly improve skin health.  Through multiple initiatives, activities, and actions, AID provides support, resources, and a nexus for individuals and organizations who are affecting change in dermatology by creating a next generation of innovative and impactful products.

About LEO Science & Tech Hub

The LEO Science & Tech Hub is an R&D innovation unit of LEO Pharma dedicated to identifying, developing, and funding innovative solutions that improve the lives of people with skin diseases. It was founded in 2016 as a catalyst to transform early-stage innovations into solutions for improving the lives of people with skin diseases. We collaborate, explore cutting-edge ideas and make investments. We are an agile group of scientific experts with an entrepreneurial mindset and a vision of how to give patients control over disease by predicting, diagnosing, and monitoring conditions. The LEO Science & Tech Hub is based in Cambridge, Mass.

Read more
Oct. 2018 24 LEO Science & Tech Hub Partners with Wearifi and Northwestern University to Develop Wearable Device for Dermatology Research

CAMBRIDGE, Mass.–(BUSINESS WIRE)–LEO Science & Tech Hub, the Boston-based R&D innovation unit of LEO Pharma, announced today that they will partner with Wearifi Inc. and the Center for Bio-Integrated Electronics at Northwestern University to investigate the clinical potential of next-generation wearable electronics in dermatology research. Wearifi designs and develops the world’s smallest, battery-free wearable device. The collaboration will evaluate whether the device and miniaturized sensor technology can inform and enhance drug development and treatment regimens by potentially identifying and measuring key disease-associated biomarkers.

Photo Credit: Wearifi Inc. and the Center for Bio-Integrated Electronics, Northwestern University (Photo Business Wire).

“We are excited to be working with LEO Science & Tech Hub on developing next generation wearables that have the potential to enable personalized medicine for patients suffering from inflammatory skin disease. Natural byproducts from skin metabolism represent a powerful opportunity for biomarker discovery that may create new approaches to diagnose disease, predict clinical deteriorations, and track individual treatment responses,” says Steve Xu MD, Medical Director of the Center for Bio-Integrated Electronics and Instructor in the Department of Dermatology at Northwestern University.

“Wearifi’s miniature wireless devices allow for imperceptible and unobtrusive placement practically anywhere on the body and are currently used to monitor heart rate, respiration rate and UV exposure,” says Anthony Banks, Chief Technology Officer for Wearifi Inc. “Partnering with a leading biopharmaceutical company like LEO to leverage this mm-scale sensor technology could potentially open new avenues to advance skin health.”

“Effectively bringing Wearifi products into the dermatology space will be a challenging endeavor, but one that will push boundaries and help us better understand our limits with regards to the relationship between technology and skin health. We have an opportunity in front of us to learn informative new details about our largest organ and potentially yield pioneering results for our industry,” says Troels Marstrand, Chief Data Scientist at LEO Science & Tech Hub. Initial steps will include a proof of concept study in collaboration with dermatologists and engineers at Northwestern University’s Center for Bio-Integrated Electronics and Northwestern University Feinberg School of Medicine’s Department of Dermatology. The teams involved will explore the feasibility of creating a wearable Volatile Organic Compound (VOC) detector for continuous measurement of both external and internal VOCs.

The LEO Science & Tech Hub is recognized for its unique collaborative approach of seeking cutting-edge technology for dermatological applications. Since its launch, the Hub has successfully formed multiple partnerships to explore minimally invasive biomarker technologies, drug delivery devices, advanced imaging systems and remote monitoring methods with leading research institutes and biotechnology companies including MITEpicore BiosystemsThe Karp LabNovopyxis,Elektrofi and The Wellman Center for Photomedicine at Massachusetts General Hospital.

About Wearifi Inc.
Wearifi Inc. is a spinout from the John Rogers’ Laboratory at Northwestern University’s Center for Bio-Integrated electronics. Wearifi Inc. is revolutionizing wearables through miniaturized sensors small enough to fit on fingernails that work completely battery-free. The company has established development partnerships with multinational companies including L’Oreal, and funding from the U.S. Department of Defense and the National Institutes of Health. For more information, please visit www.wearifi.net or email info@wearifi.net.

About Northwestern University’s Center for Bio-Integrated Electronics
The Center for Bio-Integrated Electronics (CBIE) was established in 2016 by Prof. John Rogers as part of the Simpson Querrey Institute for BioNanotechnology. The CBIE supports fundamental, applied and translational biomedical research to develop soft, biocompatible forms of bioelectronics with unique functionality that could fundamentally transform health care. For more information please visit http://bioelectronics.northwestern.edu or email cbie@northwestern.edu.

About LEO Science & Tech Hub
The LEO Science & Tech Hub is an R&D innovation unit of LEO Pharma dedicated to identifying, developing, and funding innovative solutions that improve the lives of people with skin diseases. It was founded in 2016 as a catalyst to transform early-stage innovations into solutions for improving the lives of people with skin diseases. We collaborate, explore cutting-edge ideas and make investments. We are an agile group of scientific experts with an entrepreneurial mindset and a vision of how to give patients control over disease by predicting, diagnosing, and monitoring conditions. The LEO Science & Tech Hub is based in Cambridge, Mass. For more information, please visit www.leo-scitech.com, or connect with us at engage@leo-scitech.com, on Twitter @LEOscitech or LinkedIn www.linkedin.com/company/leo-science-&-tech-hub/

Contacts

LEO Science & Tech Hub
Alex Ignatius Costa
AGXDK@leo-pharma.com
or
Media Contact:
LaVoieHealthScience
Anthony Karamourtopoulos, 617-374-8800 ext. 104
akara@lavoiehealthscience.com
or
Wearifi Inc.
Anthony Banks
abank@mywearifi.com

Read more
Contact

We want to engage with partners that have unique innovative skills to generate solutions that will improve the quality of life of patients with skin disease.

Tel. +1 201 396 1645
michael.sierra@leo-scitech.com
LinkedIn

Michael Sierra Vice President Email me